Cargando…
FRI018 A Novel Truncating Variant Of EBF2 Disrupts Human Adipocyte Differentiation In Lipodystrophy Syndromes: An Example Of A Discovery From A Clinical Translational Pipeline
Disclosure: M.C. Foss de Freitas: Advisory Board Member; Self; PTC Therapeutics. N. Wys: None. M. Udler: None. L. Pais: None. A. Monteiro da Rocha: None. O.A. MacDougald: None. E.A. Oral: Consulting Fee; Self; Regeneron Pharmaceuticals, Aegerion Pharmaceuticals, Ionis Pharmaceuticals Inc., Third Roc...
Autores principales: | Foss de Freitas, Maria Cristina, Wys, Noel, Udler, Miriam, Pais, Lynn, da Rocha, Andre Monteiro, MacDougald, Ormond A, Oral, Elif A, Chun, Tae-Hwa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554840/ http://dx.doi.org/10.1210/jendso/bvad114.029 |
Ejemplares similares
-
386 A novel truncating variant of EBF2 disrupts human adipocyte differentiation in lipodystrophy syndromes: an example of a discovery from a clinical translational pipeline
por: Foss-Freitas, Maria C., et al.
Publicado: (2023) -
FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023) -
FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023) -
FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023) -
Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)